| RESEARCH PAPER |
|
|
|
| Year : 2004 | Volume
: 36
| Issue : 1 | Page : 38-40 |
| |
Antitumor activity of Indigofera aspalathoides on Ehrlich ascites carcinoma in mice
B Rajkapoor , B Jayakar , N Murugesh
Department of Pharmacology, Vinayaka Mission’s College of Pharmacy, Yercaud Road, Salem - 636008, India
Correspondence Address:
Department of Pharmacology, Vinayaka Mission’s College of Pharmacy, Yercaud Road, Salem - 636008, India
[email protected]
Objective: To evaluate the antitumor activity of the ethanol extract of Indigofera aspalathoides (EIA) in mice.
Material and Methods: The antitumor activity of EIA was evaluated against the Ehrlich ascites carcinoma (EAC) tumor model. The activity was assessed using survival time, peritoneal cell count, hematological studies, solid tumor mass and in vitro cytotoxicity.
Results: Oral administration of EIA increased the survival time and normal peritoneal cell count. Hematological parameters, protein and PCV, which were altered by tumor inoculation, were restored. Solid tumor mass was also significantly reduced. EIA was found to be cytotoxic in the in vitro model.
Conclusion: EIA possesses significant antitumor activity.
How to cite this article:
Rajkapoor B, Jayakar B, Murugesh N. Antitumor activity of Indigofera aspalathoides on Ehrlich ascites carcinoma in mice. Indian J Pharmacol 2004;36:38-40 |
How to cite this URL:
Rajkapoor B, Jayakar B, Murugesh N. Antitumor activity of Indigofera aspalathoides on Ehrlich ascites carcinoma in mice. Indian J Pharmacol [serial online] 2004 [cited 2023 Sep 28];36:38-40. Available from: https://www.ijp-online.com/text.asp?2004/36/1/38/6792 |
Introduction
A number of natural products have been studied for anticancer activity on various experimental models. This has resulted in the availability of nearly 30 effective anticancer drugs.[1] Indigofera aspalathoides Vahl (Family: Papilionaceae) is a low undershrub with wide distribution, mostly found in South India and Sri Lanka. The stem is traditionally used for various skin disorders and cancer.[2] The plant is popularly known as Sivanar vembu in Tamil. The aim of the present study was to evaluate the antitumour activity of the ethanol extract of Indigofera aspalathoides (EIA) against Ehrlich ascites carcinoma (EAC) in mice.
Material and Methods
Collection and extraction
Stems of Indigofera aspalathoides were collected in and around Salem district in the month of December 2002 and authenticated by Dr. G. Murthy, Botanical Survey of India, Coimbatore, Tamil Nadu, India. The stems were shade-dried and pulverized. The powder was treated with petroleum ether for dewaxing and removal of chlorophyll. Later, it was packed (250 g) in a Soxhlet apparatus and subjected to hot continuous percolation for 8 h by using 450 ml of ethanol (95% v/v) as solvent. The extract was concentrated under vacuum and dried in a desiccator (yield, 11.25 g, 4.5% w/w) and suspended in 5% gum acacia for pharmacological[3] studies.
Animals
Adult Swiss male albino mice (20-25 g) were procured from Perundurai Medical College, Perundurai, Tamil Nadu and used throughout the study. They were housed in microlon boxes in a controlled environment (temperature 25+20C and 12 h dark/light cycle) with standard laboratory diet and water ad libitum. The study was conducted after obtaining Institutional animal ethical committee clearance.
Cells
EAC cells were obtained through the courtesy of Amala Cancer Research Center, Thrissur. They were maintained by weekly intraperitoneal inoculation of 10 6 cells/mouse.[4]
Effect of EIA on survival time[5]
Animals were inoculated with 1 X 10 6 cells/mouse on day '0' and treatment with EIA started 24 h after inoculation, at a dose of 250 mg/kg/day, p.o. The control group was treated with the same volume of 0.9% sodium chloride solution. All the treatments were given for nine days. The median survival time (MST) of each group, consisting of 10 mice was noted. The antitumor efficacy of EIA was compared with that of 5-fluorouracil (Dabur Pharmaceutical Ltd, India; 5-FU, 20 mg/kg/day, i.p. for 9 days). The MST of the treated groups was compared with that of the control group using the following calculation:
Increase in lifespan = T - C X 100
C
Where T = number of days the treated animals survived and C = number of days control animals survived.
Effect of EIA on normal peritoneal cells[5]
Three groups of normal mice (n= 5) were used for the study. One group was treated with 250 mg/kg, p.o. of EIA only once for a single day and the second group received the same treatment for two consecutive days. The untreated third group was used as control. Peritoneal exudate cells were collected after 24 h treatment by repeated intraperitoneal wash with normal saline and counted in each of the treated groups and compared with those of the untreated group.
Effect of EIA on hematological parameters[5]
In order to detect the influence of EIA on the hematological status of EAC-bearing mice, a comparison was made among three groups (n= 5) of mice on the 14th day after inoculation. The groups comprised of (1) tumor-bearing mice (2) tumor-bearing mice treated with EIA (250 mg/kg/day, p.o. for the first 9 days) and (3) control mice (normal). Blood was drawn from each mouse by the retro orbital plexus method and the white blood cell count (WBC), red blood cell count (RBC), hemoglobin, protein and packed cell volume (PCV) were determined.[6],[7],[8]
Effect of EIA on solid tumor[9]
Mice were divided into two groups (n=8). Tumor cells (1 X 106 cells/mice) were injected into the right hind limb (thigh) of all the animals intramuscularly. The mice of Group I were tumor control. Group II received EIA (250 mg/kg) orally for 5 alternate days. The dose was selected based on toxicity studies which showed no toxicity up to 5 g/kg (p.o.). Tumor mass was measured from the 11th day of tumor induction. The measurement was carried out every 5th day for a period of 30 days. The volume of tumor mass was calculated using the formula V = 4/3pr2 where r is the mean of r1 and r2 which are two independent radii of the tumor mass.[10]
Effect of EIA on in vitro cytotoxicity
Short-term cytotoxicity was assessed by incubating 1 X 106 EAC cells in 1 ml phosphate buffer saline with varying concentrations of the EIA at 370C for 3 h in CO2 atmosphere ensured using a McIntosh field jar. The viability of the cells was determined by the trypan blue exclusion method.[11]
Statistical analysis
All values were expressed as mean+SEM. The data were statistically analyzed by one-way ANOVA followed by Dunnett's test, the data of hematological parameters were analyzed using ANOVA followed by Tukey multiple comparison test and data of solid tumor were analyzed using Student's ' t ' test. P values <0.05 were considered significant.
Results
The effect of EIA on the survival of tumor-bearing mice is shown in [Table - 1]. The MST for the control group was 21+1.20 days, whereas it was 33+1.20 days and 40+2.10 days for the groups treated with EIA (250 mg/kg/day, p.o.) and 5-FU (20 mg/kg/day, i.p.) respectively. The increase in the lifespan of tumor-bearing mice treated with EIA and 5-FU was found to be 57.14% and 90.47% respectively (P< 0.01) as compared to the control group.
The average number of peritoneal exudate cells per normal mouse was found to be 5.8+0.4 X 106. Single treatment with EIA (250 mg/kg) enhanced peritoneal cells to 8.9+0.9 X 106, while two consecutive treatments enhanced the number to 9.8+1.1 X 106 (P< 0.001).
Hematological parameters of tumor-bearing mice on Day 14 showed significant changes when compared with the normal mice [Table - 2]. The total WBC count, proteins and PCV were found to increase with a reduction in the hemoglobin content of RBC. The differential count of WBC showed that the percentage of neutrophils increased (P<0.001) while that of lymphocytes decreased (P<0.001). At the same time interval, EIA (250 mg/kg/day, p.o.) treatment could change these altered parameters to near normal.
There was reduction in the tumor volume of mice treated with EIA (P<0.001). Tumor volume of control animals was 2.96+0.12 ml, whereas for the extract-treated group it was 1.54+0.05 ml. The in vitro cytotoxicity study showed the IC50 of EIA to be 500+11.54 mg/ml.
Discussion
The reliable criteria for judging the value of any anticancer drug are prolongation of lifespan and decrease of WBC from blood.[12],[13] The results of the present study show an antitumor effect of EIA against EAC in Swiss albino mice. A significant enhancement of MST and peritoneal cell count was observed.
The effect of EIA treatment on the peritoneal exudate cells of normal mice is an indirect method of evaluating its inhibitory effect on tumor cell growth. Normally, a mouse contains about 5 X 106 peritoneal cells, 50% of which are macrophages. EIA treatment was found to enhance peritoneal cells count. These results demonstrate the indirect inhibitory effect of EIA on EAC cells, which is probably mediated by the enhancement and activation of either macrophage or cytokine production.
The analysis of the hematological parameters showed minimum toxic effect in mice treated with EIA. After 14 days of transplantation, EIA was able to reverse the changes in the hematological parameters consequent to tumor inoculation. The present study reveals that the extract was cytotoxic towards EAC.
Preliminary phytochemical screening indicated the presence of alkaloids and flavonoids in EIA. Flavonoids have been shown to possess antimutagenic and antimalignant effects.[14],[15] Moreover, flavonoids have a chemopreventive role in cancer through their effects on signal transduction in cell proliferation[16] and angiogenesis.[17] The cytotoxic and antitumor properties of the extract may be due to these compounds. The present study points to the potential anticancer activity of Indigofera aspalathoides. Further studies to characterize the active principles and elucidate the mechanism of the action of EIA are in progress.
| » References | |  |
| 1. | Ramakrishna Y, Manohor AI, Mamata P, Shreekant KG. Plants and novel antitumour agents: A review. Indian Drugs 1984;21:173-85.  |
| 2. | Anonymous, Wealth of India, Raw Materials. Vol.V. New Delhi: Publication and Information Directorate (CSIR); 2001. |
| 3. | Suffness M, Douros J. In: Devita VT, editor. Methods in cancer research. New York: Academic Press; 1978. p. 73-5. |
| 4. | Gothoskar SV, Ranadive KJ. Anticancer screening of SAN-AB: An extract of marking nut Semicarpus anacardium. Indian J Exp Biol 1971;9:372-5. |
| 5. | Sur P, Ganguly DK. Tea plant root extract (TRE) as an antineoplastic agent. Planta Med 1994;60:106-9. [PUBMED] |
| 6. | D'Amour FF, Blood FR, Belden DA. The Manual for laboratory work in mammalian physiology. Chicago: The University of Chicago Press; 1965. |
| 7. | Lowry OH, Rosenbrough NT, Farr AL. Protein measurement with Folin - Phenol reagent. J Biol Chem 1951;173:265-75. |
| 8. | Docie JV. Practical haematology. 2nd ed. London: J&A Churchill Ltd; 1958. |
| 9. | Ramnath V, Kuttan G, Kuttan R. Antitumour effect of abrin on transplanted tumours in mice. Indian J Physiol Pharmacol 2002;46:69-77. |
| 10. | Kuttan G, Vasudevan DM, Kuttan R. Effect of a preparation from Viscum album on tumour development in vitro and in mice. J Ethnopharmacol 1990;29:35-41. |
| 11. | Sheeja KR, Kuttan G, Kuttan R. Cytotoxic and antitumour activity of Berberin. Amala Res Bull 1997;17:73-6. |
| 12. | Clarkson BD, Burchenal JH. Preliminary screening of antineoplastic drugs. Prog Clin Cancer 1965;1:625-9. |
| 13. | Oberling C, Guerin M. The role of viruses in the production of cancer. Adv Cancer Res 1954;2:353-423. |
| 14. | Brown JP. A review of the genetic effect of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res 1980;75:243-7. |
| 15. | Hirano T, Oka K, Akiba M. Antiproliferative effect of synthetic and naturally occurring flavonoids on tumour cells of human breast carcinoma cell lines, ZR-75-1. Res Commun Chem Pathol Pharmacol 1989;64:69-78. |
| 16. | Weber G, Shen F, Prajda N, Yeh YA, Yang H, Herenyiova, et al. Increased signal transduction activity and down regulation in human cancer cells. Anticancer Res 1996;16:3271-82. |
| 17. | Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997;57:2916-21. |
|
|
 |
|
|
|
|
